Tema Etfs LLC Takes $85,000 Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Tema Etfs LLC acquired a new position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 14,960 shares of the company’s stock, valued at approximately $85,000.

A number of other institutional investors and hedge funds also recently modified their holdings of VYGR. Rhumbline Advisers grew its holdings in Voyager Therapeutics by 3.4% during the fourth quarter. Rhumbline Advisers now owns 71,497 shares of the company’s stock worth $405,000 after purchasing an additional 2,354 shares during the period. Empowered Funds LLC boosted its stake in shares of Voyager Therapeutics by 5.3% during the 4th quarter. Empowered Funds LLC now owns 47,206 shares of the company’s stock worth $268,000 after acquiring an additional 2,397 shares during the period. Wells Fargo & Company MN increased its holdings in shares of Voyager Therapeutics by 3.7% during the 4th quarter. Wells Fargo & Company MN now owns 66,718 shares of the company’s stock worth $378,000 after acquiring an additional 2,400 shares during the last quarter. Picton Mahoney Asset Management raised its stake in Voyager Therapeutics by 71.1% in the 4th quarter. Picton Mahoney Asset Management now owns 5,883 shares of the company’s stock valued at $33,000 after acquiring an additional 2,444 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in Voyager Therapeutics by 133.4% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company’s stock valued at $31,000 after acquiring an additional 3,077 shares during the period. 48.03% of the stock is owned by institutional investors.

Voyager Therapeutics Stock Performance

VYGR opened at $3.30 on Monday. Voyager Therapeutics, Inc. has a 52-week low of $2.75 and a 52-week high of $9.55. The firm has a market cap of $182.61 million, a P/E ratio of 4.65 and a beta of 0.95. The business’s fifty day moving average is $3.43 and its 200-day moving average is $4.78.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, May 6th. The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.18). Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. The firm had revenue of $6.47 million during the quarter, compared to analyst estimates of $13.55 million. On average, research analysts predict that Voyager Therapeutics, Inc. will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at Voyager Therapeutics

In other news, CEO Alfred Sandrock sold 10,885 shares of Voyager Therapeutics stock in a transaction on Wednesday, April 2nd. The stock was sold at an average price of $3.43, for a total value of $37,335.55. Following the transaction, the chief executive officer now owns 430,931 shares in the company, valued at approximately $1,478,093.33. This trade represents a 2.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 6.39% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on VYGR shares. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a research report on Tuesday, April 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Voyager Therapeutics in a research report on Wednesday, March 12th. Wedbush reissued an “outperform” rating on shares of Voyager Therapeutics in a report on Wednesday, March 12th. Wells Fargo & Company set a $10.00 price target on Voyager Therapeutics and gave the company an “overweight” rating in a research note on Wednesday, March 12th. Finally, Canaccord Genuity Group dropped their target price on Voyager Therapeutics from $14.00 to $12.00 and set a “buy” rating for the company in a report on Thursday, March 13th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Voyager Therapeutics currently has an average rating of “Buy” and an average target price of $13.39.

Voyager Therapeutics Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.